Clinical Trials Sponsored by Hutchison Medipharma Limited

Total 135 results

Hutchison Medipharma Limited

Recruiting

A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
Hutchison Medipharma Limited

Recruiting

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (SANOVO)

Non-small Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer Metastatic

China
Hutchison Medipharma Limited

Recruiting

A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
BeiGene
Hutchison Medipharma Limited

Completed

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Advanced Solid Tumors

Korea, Republic of, China
Hutchison Medipharma Limited

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

Lymphomas

China
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Hutchison Medipharma Limited

Unknown

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

Immune Thrombocytopenia (ITP)

China
Hutchison Medipharma Limited

Completed

Phase II Study of HMPL-004 in Patients With Ulcerative Colitis

Ulcerative Colitis
Hutchison Medipharma Limited

Completed

Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors (HMPL)

Tumor

China
Hutchison Medipharma Limited

Unknown

A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Acute Myeloid Leukemia

China
Hutchison Medipharma Limited

Unknown

A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

Mature B-cell Neoplasms

China
Hutchison Medipharma Limited

Completed

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

Cancer

China
Hutchison Medipharma Limited

Terminated

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

United States
Hutchison Medipharma Limited

Withdrawn

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Lung Cancer

China
Hutchison Medipharma Limited

Completed

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

Rheumatoid Arthritis (RA)

Australia
Hutchison Medipharma Limited

Recruiting

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma With EZH2

China
Hutchison Medipharma Limited

Recruiting

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin's Lymphoma

China
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

China
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
Hutchison Medipharma Limited

Active, not recruiting

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

Metastatic Colorectal Cancer | Metastatic Colon Cancer

United States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
Hutchison Medipharma Limited

Completed

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Healthy Subject

China
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Hutchison Medipharma Limited

Active, not recruiting

Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP)

China
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Hutchison Medipharma Limited

Completed

Surufatinib DDI With a PPI and a CYP3A Inducer

Healthy

United States
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Healthy

United States
Hutchison Medipharma Limited

Unknown

HMPL-813 in Treating Patients With Glioblastoma

Glioblastoma

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Healthy

China
Hutchison Medipharma Limited

Completed

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Solid Tumor

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Hutchison Medipharma Limited

Unknown

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor, Adult

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Hutchison Medipharma Limited

Completed

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Crohn's Disease
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Hutchison Medipharma Limited

Terminated

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor

Australia
Hutchison Medipharma Limited

Completed

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Hutchison Medipharma Limited

Recruiting

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT

Advanced Malignant Solid Tumors | TGCT

China
Hutchison Medipharma Limited

Recruiting

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Solid Tumor

China

3

Subscribe